On February 12th 2021 the FDA approved COSELA™ (trilaciclib) as the first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression. The product was launched in the US market on March 2nd 2021.
Fermion is proud of its customer’s success with the development of the NCE which will help patients undergoing chemotherapy treatment for their extensive-stage small cell lung cancer. The collaboration between Fermion and G1 started already 5 years ago and it has been a great learning journey for both companies. Working together with the G1 team Fermion has once again proven its capability to support customers from the clinical stage through to commercialization and production.